# Nutritional supplement sprinkles with zinc and micronutrients

Submission date 12/02/2010	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 16/03/2010	<b>Overall study status</b> Completed	<ul> <li>Statistical analysis plan</li> <li>Results</li> </ul>
Last Edited 15/03/2011	<b>Condition category</b> Nutritional, Metabolic, Endocrine	<ul> <li>Individual participant data</li> <li>Record updated in last year</li> </ul>

## Plain English summary of protocol

Not provided at time of registration

## **Contact information**

**Type(s)** Scientific

**Contact name** Dr Nelly Zavaleta

**Contact details** 

Av. La Molina 1885 La Molina Lima Peru Lima 12

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers IIN-270

# Study information

Scientific Title

Efficacy of the nutritional supplement sprinkles with zinc and micronutrients on anaemia and acute diarrhoea in Peruvian children

#### Acronym

SUNSZIM

#### **Study objectives**

1. Children 6 to 17 months of age that consume the nutritional supplement sprinkles with zinc and micronutrients for a 6 month period will have a lower prevalence of anaemia than will those children that consume the nutritional supplement sprinkles with iron alone.

2. Children 6 to 17 months of age that consume the nutritional supplement sprinkles with zinc and micronutrients for a 6 month period will have a lower incidence and prevalence of acute diarrhoea than will those children that consume the nutritional supplement sprinkles with iron alone.

3. Children 6 to 17 months of age that consume the nutritional supplement sprinkles with zinc and micronutrients for a 6 month period will have better growth than those children that consume the nutritional supplement sprinkles with iron alone.

4. The adherence of the nutritional supplement sprinkles with zinc and micronutrients and the nutritional supplement sprinkles with iron alone will be similar, in both cases greater than 75% of the offered doses.

## Ethics approval required

Old ethics approval format

#### Ethics approval(s)

1. Instituto de Investigacion Nutricional (IIN) Institutional Review Board (IRB) approved on the 26th of June 2009 (ref: 284-2009/CEI-IIN)

2. Mount Sinai Hospital IRB approved on the 22nd of October 2009

3. Peruvian NIH authorisation received on the 18th of September 2009

#### Study design

Interventional single centre phase III double blind randomised controlled trial

## Primary study design

Interventional

Secondary study design Randomised controlled trial

**Study setting(s)** Other

**Study type(s)** Prevention

#### Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet (in Spanish)

## Health condition(s) or problem(s) studied

Anaemia and diarrhoea

#### Interventions

#### Research product:

Micronutrient supplement as sprinkles, packaged into individual sachets, each sachet intended for once daily use to be mixed with food. The iron portion of the powder is lipid encapsulated to prevent changing the taste, texture, or colour of the food. The composition used in this study is outlined in the table below.

Micronutrient Amount Iron as fumarate 12.5mg Zinc as gluconate 10 mg Folic Acid 160mcg Vitamin A 300mcg RE Vitamin C 30mg

Control Product:

The control group is also a powdered sprinkles form having the following composition per sachet. Micronutrients Quantity Iron as fumarate 12.5mg Route of administration (both groups): Oral Presentation Form: Powder Duration of supplementation per subject: 6 months.

#### Intervention Type

Other

Phase

Phase III

#### Primary outcome measure

1. Anemia:

Haemoglobin (Hb) is measured by HemoCue® at baseline and 6 months later (end of the study participation). Prevalence of anaemia is the percentage of children with Hb below 11 g/dl (WHO definition). We will also compare mean Hb values at baseline and end of the study. 2. Diarrhoea:

Morbidity is recorded by home surveillance once a week and we register the daily morbidity, prevalence of diarrhoea is registered as the days with morbidity over the number of observation days x 100, incidence as number of episodes of diarrhoea per 100 days of observations.

#### Secondary outcome measures

1. Incidence of severe diarrhoea:

Severe diarrhoea is defined as  $\geq$  6 liquid or loose stools in the last 24 hr, number of episodes of severe diarrhoea per 100 days of observations.

2. Duration of diarrhoea:

Number of days with diarrhoea (  $\geq$  3 liquid or loose stools in the last 24 hr).

3. Adherence to supplementation:

Number of sachets consumed during the study per over the number of sachets given x 100. 4. Changes in weight and length:

Anthropometric measures weight and length will be taken on infants at baseline and monthly through 6 months of intervention, and Z scores determined for weight-for-age (WAZ), length-for-

age (LAZ), and weight-for-length (WLZ) compared to WHO references. 5. Serum zinc: Measured at entry and 6 months post supplementation.

#### Overall study start date

07/01/2010

#### **Completion date**

31/01/2011

# Eligibility

#### Key inclusion criteria

- 1. Aged between 6 months and 17 months, 29 days of age
- 2. Residents of Villa El Salvador, Lima, Peru
- 3. Born at term
- 4. Birth weight equal or higher than 2500g
- 5. Healthy
- 6. Parents agree to sign the informed consent form

## Participant type(s)

Patient

Age group Child

-----

**Lower age limit** 6 Months

#### Upper age limit

17 Months

Sex

Both

# Target number of participants

902

#### Key exclusion criteria

1. Age less than 6 months, or equal to/greater than 18 months

- 2. Not residents in the area of intervention
- 3. Children with an initial haemoglobin equal to or less than 8g/dL will be evaluated by a doctor to rule out some additional pathology and will receive treatment according to Peruvian Ministry
- of Health (Ministerio de Salud [MINSA]) norms
- 4. Weight/Length less than -2 Standard Deviations (SD)
- 5. Any chronic, congenital, or severe illnesses
- 6. Children that regularly consume other micronutrient supplements

## Date of first enrolment

07/01/2010

Date of final enrolment 31/01/2011

## Locations

**Countries of recruitment** Peru

**Study participating centre Av. La Molina 1885** Lima Peru Lima 12

# Sponsor information

**Organisation** Instituto de Investigación Nutricional (IIN) (Peru)

**Sponsor details** Av. La Molina 1885 La Molina Lima Peru Lima 12

**Sponsor type** Research organisation

ROR https://ror.org/05by4rq81

# Funder(s)

**Funder type** Charity

**Funder Name** United Nations Children's Fund (UNICEF) (USA)

# **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration